Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.

Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST.

J Neurosci. 2007 Jun 6;27(23):6174-84.

2.

High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types.

Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O'Keefe GJ, Masters CL, Mori H, Rowe CC.

Arch Neurol. 2009 Dec;66(12):1537-44. doi: 10.1001/archneurol.2009.285.

PMID:
20008660
3.

Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers.

Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodríguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN.

Brain. 2011 Jan;134(Pt 1):293-300. doi: 10.1093/brain/awq310. Epub 2010 Nov 16.

PMID:
21084313
4.

Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA.

J Neurosci. 2005 Nov 16;25(46):10598-606.

5.

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.

Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Schöll M, Chiotis K, Thordardottir S, Graff C, Wall A, Långström B, Nordberg A.

Brain. 2016 Mar;139(Pt 3):922-36. doi: 10.1093/brain/awv404. Epub 2016 Jan 26.

6.

Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation.

Schöll M, Almkvist O, Axelman K, Stefanova E, Wall A, Westman E, Långström B, Lannfelt L, Graff C, Nordberg A.

Neurobiol Aging. 2011 Aug;32(8):1388-99. doi: 10.1016/j.neurobiolaging.2009.08.016. Epub 2009 Sep 30.

PMID:
19796846
7.

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.

Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, Langbaum JB, Ayutyanont N, Roontiva A, Thiyyagura P, Lee W, Mo H, Lopez L, Moreno S, Acosta-Baena N, Giraldo M, Garcia G, Reiman RA, Huentelman MJ, Kosik KS, Tariot PN, Lopera F, Reiman EM.

Lancet Neurol. 2012 Dec;11(12):1057-65. doi: 10.1016/S1474-4422(12)70227-2. Epub 2012 Nov 6.

8.

Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.

Förster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Förstl H, Kurz A, Grimmer T, Drzezga A.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1927-36. doi: 10.1007/s00259-012-2230-9. Epub 2012 Aug 28.

PMID:
22926714
9.

PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease.

Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, Någren K, Rokka J, Haaparanta M, Kalimo H, Rinne JO.

Brain. 2008 Jul;131(Pt 7):1845-53. doi: 10.1093/brain/awn107. Epub 2008 Jun 25.

PMID:
18583368
10.

Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.

Schöll M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Långström B, Almkvist O, Graff C, Nordberg A.

Neurology. 2012 Jul 17;79(3):229-36. doi: 10.1212/WNL.0b013e31825fdf18. Epub 2012 Jun 13.

PMID:
22700814
11.

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B.

Ann Neurol. 2004 Mar;55(3):306-19.

PMID:
14991808
12.

Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.

Laforce R Jr, Tosun D, Ghosh P, Lehmann M, Madison CM, Weiner MW, Miller BL, Jagust WJ, Rabinovici GD.

Neuroimage Clin. 2014 Mar 19;4:508-16. doi: 10.1016/j.nicl.2014.03.005. eCollection 2014.

13.

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A.

Brain. 2006 Nov;129(Pt 11):2856-66. Epub 2006 Jul 19.

PMID:
16854944
14.

Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers.

Schöll M, Almkvist O, Bogdanovic N, Wall A, Långström B, Viitanen M, Nordberg A.

J Alzheimers Dis. 2011;24(3):495-506. doi: 10.3233/JAD-2011-101563.

PMID:
21297272
15.

AZD2184: a radioligand for sensitive detection of beta-amyloid deposits.

Johnson AE, Jeppsson F, Sandell J, Wensbo D, Neelissen JA, Juréus A, Ström P, Norman H, Farde L, Svensson SP.

J Neurochem. 2009 Mar;108(5):1177-86. doi: 10.1111/j.1471-4159.2008.05861.x. Epub 2009 Jan 24.

16.

Clinical and neuroimaging characterization of Chinese dementia patients with PSEN1 and PSEN2 mutations.

Shi Z, Wang Y, Liu S, Liu M, Liu S, Zhou Y, Wang J, Cai L, Huo YR, Gao S, Ji Y.

Dement Geriatr Cogn Disord. 2015;39(1-2):32-40. doi: 10.1159/000366272. Epub 2014 Oct 15.

PMID:
25323700
17.

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA.

J Cereb Blood Flow Metab. 2005 Nov;25(11):1528-47.

PMID:
15944649
18.

Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging.

Hatashita S, Yamasaki H.

J Alzheimers Dis. 2010;21(3):995-1003. doi: 10.3233/JAD-2010-100222.

PMID:
20693641
19.

Regional analysis of striatal and cortical amyloid deposition in patients with Alzheimer's disease.

Ishibashi K, Ishiwata K, Toyohara J, Murayama S, Ishii K.

Eur J Neurosci. 2014 Aug;40(4):2701-6. doi: 10.1111/ejn.12633. Epub 2014 Jun 2.

PMID:
24888235
20.

Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.

Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, Mathis CA.

Arch Neurol. 2009 Jan;66(1):60-7. doi: 10.1001/archneurol.2008.511.

Supplemental Content

Support Center